Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension

Back

ESC Professional Premium Access

Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension

Session: Molecular approaches to the treatment of pulmonary hypertension

Topic: Pulmonary Hypertension

Speaker: Doctor S. Cooper (Lexington, US)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Simon Cooper

Lexington (United States of America)

0 follower

4 more presentations in this session

State-of-the-art lecture on molecular approaches to the treatment of pulmonary hypertension

Speaker: Doctor P. Thistlethwaite (La Jolla, US)

Access

Slides

Video

Hemodynamic changes with pulmonary arterial hypertension targeted therapies: a meta-analysis of 3898 treatment-naive patients

Speaker: Mr I. Farmakis (Mainz, DE)

Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)

Speaker: Doctor K. Tello (Giessen, DE)

The effects of empagliflozin on right ventricular adaptation to pressure overload

Speaker: Ms J. Axelsen (Aarhus, DK)

Access the full session

Molecular approaches to the treatment of pulmonary hypertension

Speakers: Doctor S. Cooper, Doctor P. Thistlethwaite, Mr I. Farmakis, Doctor K. Tello, Ms J. Axelsen

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources